These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34246461)

  • 1. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment.
    Stöhr T; Colin PJ; Ossig J; Pesic M; Borkett K; Winkle P; Struys MMRF; Schippers F
    Br J Anaesth; 2021 Sep; 127(3):415-423. PubMed ID: 34246461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
    Antonik LJ; Goldwater DR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):274-83. PubMed ID: 22190555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials.
    Pesic M; Stöhr T; Ossig J; Borkett K; Donsbach M; Dao VA; Webster L; Schippers F
    Drugs R D; 2020 Sep; 20(3):267-277. PubMed ID: 32757149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics.
    Schüttler J; Eisenried A; Lerch M; Fechner J; Jeleazcov C; Ihmsen H
    Anesthesiology; 2020 Apr; 132(4):636-651. PubMed ID: 31972655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers.
    Sheng XY; Liang Y; Yang XY; Li LE; Ye X; Zhao X; Cui YM
    Eur J Clin Pharmacol; 2020 Mar; 76(3):383-391. PubMed ID: 31873765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Vitamin D Receptor, Cytochrome P450 3A, and Cytochrome P450 Oxidoreductase Genetic Polymorphisms on the Pharmacokinetics of Remimazolam in Healthy Chinese Volunteers.
    Hu K; Xiang Q; Wang Z; Sheng X; Li L; Liang Y; Zhao X; Ye X; Cui Y
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):22-29. PubMed ID: 32250057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-to-Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia.
    Lohmer LL; Schippers F; Petersen KU; Stoehr T; Schmith VD
    J Clin Pharmacol; 2020 Apr; 60(4):505-514. PubMed ID: 31989598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.
    Small DS; Zhang W; Royalty J; Cannady EA; Downs D; Ortega D; Suico JG
    Eur J Clin Pharmacol; 2016 May; 72(5):563-72. PubMed ID: 26857125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacodynamic Markov mixed-effects model for determining remimazolam-induced sedation when co-administered with fentanyl in procedural sedation.
    Zhou J; Curd L; Lohmer LRL; Delpratt N; Ossig J; Schippers F; Stoehr T; Schmith VD
    Clin Transl Sci; 2021 Jul; 14(4):1554-1565. PubMed ID: 33768731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote.
    Chen X; Sang N; Song K; Zhong W; Wang H; Jiang J; Huang Y; Hu P
    Clin Ther; 2020 Apr; 42(4):614-624. PubMed ID: 32178858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial.
    Pesic M; Schippers F; Saunders R; Webster L; Donsbach M; Stoehr T
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1505-1516. PubMed ID: 32886178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trial.
    Rex DK; Bhandari R; Lorch DG; Meyers M; Schippers F; Bernstein D
    Dig Liver Dis; 2021 Jan; 53(1):94-101. PubMed ID: 33243567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part II. Pharmacodynamics of Electroencephalogram Effects.
    Eisenried A; Schüttler J; Lerch M; Ihmsen H; Jeleazcov C
    Anesthesiology; 2020 Apr; 132(4):652-666. PubMed ID: 31972657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic analysis of intravenous bolus remimazolam for loss of consciousness in patients undergoing general anaesthesia: a randomised, prospective, double-blind study.
    Chae D; Kim HC; Song Y; Choi YS; Han DW
    Br J Anaesth; 2022 Jul; 129(1):49-57. PubMed ID: 35562226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects.
    Zhou J; Leonowens C; Ivaturi VD; Lohmer LL; Curd L; Ossig J; Schippers F; Petersen KU; Stoehr T; Schmith V
    J Clin Anesth; 2020 Nov; 66():109899. PubMed ID: 32585566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.